Statements (54)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:vaccine
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:average_temperature |
2 to 8 degrees Celsius
|
| gptkbp:brand |
gptkb:Afluria
|
| gptkbp:clinical_trial |
Phase III trials
immunization against influenza |
| gptkbp:contraindication |
severe allergic reaction to vaccine components
history of severe allergic reaction |
| gptkbp:developed_by |
gptkb:Seqirus
|
| gptkbp:dosage_form |
0.5 m L
|
| gptkbp:effective_date |
gptkb:2010
|
| gptkbp:formulation |
inactivated virus
|
| gptkbp:frequency |
gptkb:annually
|
| https://www.w3.org/2000/01/rdf-schema#label |
Afluria
|
| gptkbp:indication |
prevention of seasonal influenza
|
| gptkbp:ingredients |
contains H1 N1, H3 N2, and B strains
inactivated influenza virus |
| gptkbp:is_used_for |
influenza prevention
|
| gptkbp:is_vulnerable_to |
seasonal
healthcare professional varies by location varies by season public health programs refrigerated ongoing studies quadrivalent immunocompromised individuals updated annually adverse event reporting system based on previous influenza strains depends on match with circulating strains reduces influenza-related hospitalizations |
| gptkbp:label |
contains prescribing information
|
| gptkbp:manager |
intramuscular injection
|
| gptkbp:manufacturer |
gptkb:Seqirus
|
| gptkbp:market |
ongoing
|
| gptkbp:marketed_as |
multiple countries
|
| gptkbp:provides_information_on |
CDC recommendations
|
| gptkbp:public_awareness |
reducing influenza burden
|
| gptkbp:research_focus |
improving efficacy
|
| gptkbp:safety_features |
generally well tolerated
|
| gptkbp:side_effect |
gptkb:Guillain-Barré_syndrome
fatigue headache allergic reactions fever pain at injection site muscle aches |
| gptkbp:suitable_for |
high-risk populations
individuals with egg allergies |
| gptkbp:target_audience |
adults and children 6 months and older
|
| gptkbp:trigger_type |
suspension for injection
|
| gptkbp:bfsParent |
gptkb:Bayer_Health_Care
|
| gptkbp:bfsLayer |
3
|